{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:52:55Z","timestamp":1794541975861,"version":"4.9.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Geriatric assessment (GA) predicts survival among older adults with acute myeloid leukemia (AML) treated intensively. We evaluated the predictive utility of GA among older adults treated with low-intensity therapy on a multisite trial. We conducted a companion study (CALGB 361101) to a randomized phase 2 trial (CALGB 11002) of adults \u226560 years and considered \u201cunfit\u201d for intensive therapy, testing the efficacy of adding bortezomib to decitabine therapy. On 361101, GA and quality of life (QOL) assessment was administered prior to treatment and every other subsequent cycle. Relationships between baseline GA and QOL measures with survival were evaluated using Kaplan-Meier estimation and Cox proportional hazards models. One-hundred sixty-five patients enrolled in CALGB 11002, and 96 (52%) of them also enrolled in 361101 (median age, 73.9 years). Among participants, 85.4% completed \u22651 baseline assessment. In multivariate analyses, greater comorbidity (hematopoietic cell transplantation-specific comorbidity index &amp;gt;3), worse cognition (Blessed Orientation-Memory-Concentration score &amp;gt;4), and lower European Organization for Research and Treatment of Cancer global QOL scores at baseline were significantly associated with shorter overall survival (P &amp;lt; .05 each) after adjustment for Karnofsky Performance Status, age, and treatment arm. Dependence in instrumental activities of daily living and cognitive impairment were associated with 6-month mortality (hazard ratio [HR], 3.5; confidence interval [CI], 1.2-10.4; and HR, 3.1; CI, 1.1-8.6, respectively). GA measures evaluating comorbidity, cognition, and self-reported function were associated with survival and represent candidate measures for screening older adults planned to receive lower-intensity AML therapies. This trial was registered at www.clinicaltrials.gov as #NCT01420926 (CALGB 11002).<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006872","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T15:02:53Z","timestamp":1649948573000},"page":"3812-3820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8150-5542","authenticated-orcid":false,"given":"Ellen K.","family":"Ritchie","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6262-1123","authenticated-orcid":false,"given":"Heidi D.","family":"Klepin","sequence":"additional","affiliation":[{"name":"2Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Storrick","sequence":"additional","affiliation":[{"name":"3Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-4162","authenticated-orcid":false,"given":"Brittny","family":"Major","sequence":"additional","affiliation":[{"name":"3Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-7430","authenticated-orcid":false,"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"3Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"4Dana-Farber\/Partners Cancer Care, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Walker","sequence":"additional","affiliation":[{"name":"5Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"6Section of Hematology\/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"2022062715232840300_B1","author":"National Cancer Institute"},{"issue":"15","key":"2022062715232840300_B2","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022062715232840300_B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"issue":"5","key":"2022062715232840300_B4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia."},{"key":"2022062715232840300_B5","author":"Klepin"},{"issue":"21","key":"2022062715232840300_B6","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2022062715232840300_B7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res."},{"issue":"22","key":"2022062715232840300_B8","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022062715232840300_B9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program","volume":"6","author":"Mohile","year":"2020","journal-title":"JAMA Oncol."},{"issue":"6","key":"2022062715232840300_B10","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: a systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica."},{"issue":"10","key":"2022062715232840300_B11","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1532-5415.2011.03614.x","article-title":"The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"59","author":"Klepin","year":"2011","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"2022062715232840300_B12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgo.2019.10.002","article-title":"Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: report of CALGB 361006 (Alliance)","volume":"11","author":"Klepin","year":"2020","journal-title":"J Geriatr Oncol."},{"issue":"10","key":"2022062715232840300_B13","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14301","article-title":"Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia","volume":"64","author":"Klepin","year":"2016","journal-title":"J Am Geriatr Soc."},{"issue":"2","key":"2022062715232840300_B14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica."},{"issue":"11","key":"2022062715232840300_B15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts non-fatal toxicities and survival for intensively treated elderly acute myeloid leukemia: a prospective study","volume":"139","author":"Min","year":"2022","journal-title":"Blood."},{"key":"2022062715232840300_B16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-015-1432-5","article-title":"DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients &gt;60\u00a0years with acute myeloid leukemia who are ineligible for induction chemotherapy","volume":"15","author":"Grishina","year":"2015","journal-title":"BMC Cancer."},{"issue":"24","key":"2022062715232840300_B17","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv."},{"issue":"5","key":"2022062715232840300_B18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/bloodadvances.2016003053","article-title":"A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001","volume":"1","author":"Uy","year":"2017","journal-title":"Blood Adv."},{"issue":"10","key":"2022062715232840300_B19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022062715232840300_B20","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer."},{"issue":"8","key":"2022062715232840300_B21","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"issue":"5","key":"2022062715232840300_B22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1037\/0022-006X.51.5.730","article-title":"The structure of psychological distress and well-being in general populations","volume":"51","author":"Veit","year":"1983","journal-title":"J Consult Clin Psychol."},{"issue":"4","key":"2022062715232840300_B23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol."},{"issue":"13","key":"2022062715232840300_B24","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood."},{"issue":"2","key":"2022062715232840300_B25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cup & go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc."},{"issue":"6","key":"2022062715232840300_B26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1176\/ajp.140.6.734","article-title":"Validation of a short orientation-memory-concentration test of cognitive impairment","volume":"140","author":"Katzman","year":"1983","journal-title":"Am J Psychiatry."},{"issue":"5","key":"2022062715232840300_B27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"2022062715232840300_B28","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J Clin Oncol."},{"key":"2022062715232840300_B29","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model.","author":"Therneau","year":"2000","edition":"1st ed."},{"issue":"7","key":"2022062715232840300_B30","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22537","article-title":"Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia","volume":"109","author":"Etienne","year":"2007","journal-title":"Cancer."},{"issue":"27","key":"2022062715232840300_B31","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022062715232840300_B32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol."},{"issue":"5","key":"2022062715232840300_B33","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamaoncol.2017.5674","article-title":"Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers","volume":"4","author":"Hshieh","year":"2018","journal-title":"JAMA Oncol."},{"issue":"12","key":"2022062715232840300_B34","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022062715232840300_B35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jgo.2019.02.002","article-title":"Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes","volume":"11","author":"Jayani","year":"2020","journal-title":"J Geriatr Oncol."},{"key":"2022062715232840300_B36","article-title":"Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes","author":"Molga","year":"2019","journal-title":"J Geriatr Oncol."},{"issue":"9","key":"2022062715232840300_B37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","article-title":"Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes","volume":"37","author":"Sherman","year":"2013","journal-title":"Leuk Res."},{"issue":"19","key":"2022062715232840300_B38","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.21.00165","article-title":"Decision making in older adults with cancer","volume":"39","author":"DuMontier","year":"2021","journal-title":"J Clin Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/12\/3812\/1904366\/advancesadv2021006872.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/12\/3812\/1904366\/advancesadv2021006872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:24:09Z","timestamp":1656343449000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/12\/3812\/484927\/Geriatric-assessment-for-older-adults-receiving"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006872","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}